Can You Still Have a Baby After 40? Fertility Decline and a Decision Framework
Ovarian reserve, egg age, partner factors and treatment outcomes need separate conversations.

In this article
One. Why can a single lab result cause panic?

Actual view of the Taal Volcano lake area; unrelated to the medical evidence in this article.
In a consultation room, a 41-year-old woman slides a lab report across the desk and points to “AMH 0.6”: does this mean she has no chance left? Her anxiety is understandable—in Chinese-language internet discussions, “low AMH” and “declining ovarian function” are almost always written as if they were a countdown notice. But the true meaning of this result is much more complex than “no chance.”
AMH, or anti-Müllerian hormone, is secreted by small ovarian follicles that have not yet begun growing. Clinically, it is used to indirectly reflect “ovarian reserve”—an inventory concept describing how many usable follicles remain. A low value does suggest that reserve is declining, but it measures quantity, not the single outcome of “whether you can conceive right now.” Whether a pregnancy occurs and continues also depends on egg quality, tubal patency, the uterine environment, partner factors, and the entire picture of overall health.
This question has been raised increasingly often in recent years, against two simultaneous trends: public discussion of “pregnancy at very advanced ages” has prompted many women 40+ to reconsider their choices; and improved access to assisted reproductive technology, with some services added to insurance coverage, has made “trying to have a child” a more feasible path. But the louder the discussion gets, the more easily it is pulled toward two extreme narratives: one urges “hurry, it will be too late if you do not have a baby now,” while the other optimistically says “science is so advanced, you can always succeed if you want a baby.” This article sets both emotions aside first and discusses the evidence itself.
A more appropriate question is: what exactly changes in fertility after 40? Which changes can medical interventions address, and which cannot? When a woman with low AMH stands outside a consultation room, what she needs is not a frightening verdict but a decision framework that lays out “probability, risk, and the time window.”
First, put one statement in its proper place
Fertility declines with age as a physiological rule, but the decline is continuous, gradual, and highly individual, rather than an “automatic switch-off on a particular birthday.” Misreading “reduced reserve” as “absolute impossibility,” and misreading “there is still a chance” as “it can happen at any time,” are equally mistaken.
Two. Mechanisms: why fertility declines with age—two processes happen at once
To understand the challenge after 40, first distinguish two processes: the follicle pool gets smaller, and the quality of the remaining eggs gets worse. Assisted reproduction can partly compensate for the first by “retrieving more eggs,” but the second can hardly be overcome by increasing quantity.
1. Depletion of the follicle reserve: an irreversible curve
Women are born with nearly all their primordial follicles for life, around 1–2 million; only around 300,000–500,000 remain by puberty. Each month thereafter, a group of follicles undergoes atresia, and the reserve only declines. Classic histological tracking studies (Faddy et al., 1992; Gougeon, 2004) provide commonly cited reference estimates: tens of thousands of follicles may remain in the ovaries at age 30, around 25,000 at age 40, and fewer than 1000 near menopause. The curve is gradual in the first half of life, then declines faster after 35—this is the biological background for “age 35” as a threshold for advanced maternal age.
2. More crucial is egg quality: chromosomal aneuploidy rises with age
What truly makes pregnancy after 40 harder is not “no eggs,” but “the egg's chromosomes are abnormal.” During meiotic maturation, eggs must divide chromosomes accurately. As age increases, spindle function and homologous chromosome pairing are more likely to fail, leading to increasing numbers of aneuploid eggs (with an abnormal number of chromosomes). This directly increases two major risks: early spontaneous miscarriage (often because an embryo with chromosomal abnormalities is naturally lost) and chromosomal conditions in live-born children (such as trisomy 21).
This is clearly seen in large preimplantation genetic testing for aneuploidy (PGT-A) datasets. A study by Franasiak et al., published in Fertility and Sterility in 2014, analyzed chromosomes from trophectoderm biopsies of 15,169 blastocysts. It found that the embryonic aneuploidy rate rose steeply with maternal age: about 26.9% below age 30, over 62% above age 40, and over 90% at age 45 and above. In other words, more than half of eggs retrieved after age 40 carry chromosomal errors—retrieving a few more cannot fundamentally change this, because the errors occur in the eggs themselves, rather than resulting from too few eggs.
3. Ovarian response to stimulation also weakens
After entering a stimulated cycle, older ovaries often respond less readily to gonadotropins, yielding fewer mature follicles that can be recruited, and correspondingly fewer embryos available for biopsy or transfer. This further explains why assisted-reproduction success rates can fall “off a cliff” with age: it is the combined result of the three processes above.
4. How to locate yourself on the ovarian-reserve curve
Medicine uses a set of indicators to locate “ovarian age”: AMH reflects the resting follicle reserve; FSH and estradiol (E2) on menstrual-cycle days 2–3 reflect the ovaries' response to central signals; and the antral follicle count (AFC) on transvaginal ultrasound directly counts the small follicles visible at that time. Each has a different focus, and they complement one another—a low AMH with acceptable FSH and AFC does not mean the same thing as all three declining together. For this reason, drawing a conclusion from AMH alone is one of the most common misreadings. Looking at all three together allows a clinician to determine whether “reserve is low but quality may still be acceptable” or “reserve and quality are declining together,” then decide among trying naturally, moving promptly to assisted reproduction, or considering an egg-donation pathway earlier.
≈25,000
Common estimate of follicles remaining in the ovaries around age 40 (histological studies) [Mechanism]
62%
Embryonic chromosomal aneuploidy rate above age 40 (Franasiak 2014, n=15,169) [Academic]
90%+
Proportion of chromosomal abnormalities in embryos at age 45+ (same cohort) [Academic]
Three. Evidence review: put the figures on the table

Actual view of Kawasan Falls, Cebu; unrelated to the medical evidence in this article.
After mechanisms, we come to the numbers. The following findings recur in the literature—but remember that they are population-level probabilities, describing “the average for the same age group,” and cannot be used as a verdict on any specific individual.
Natural conception probability: declines each cycle
The Dunson team characterized how “the probability of conception in each menstrual cycle” (fecundability) changes with age using cohorts trying to conceive. A 2002 study published in Human Reproduction (n=782 couples trying to conceive) and a 2004 follow-up analysis published in Obstetrics & Gynecology jointly showed that the probability of conception per cycle was about 0.25 (around one quarter) in their 20s, falling to about 0.13 at age 35–39 and 0.06 (around 6%) at age 40–44. Over a year, around 18% of women aged 35–39 “tried for a year and still were not pregnant,” substantially more than in younger groups. These figures show that the decline is gradual, but the slope becomes markedly steeper after 40.
Spontaneous miscarriage rate: rises exponentially with maternal age
Miscarriage figures best illustrate the cost of “egg quality.” A Danish nationwide registry study by Nybo Andersen et al., published in BMJ in 2000 and including as many as 634,272 pregnancies, found that the spontaneous miscarriage rate rose from 8.9% at ages 20–24 to 74.7% after age 45—more than three-quarters of pregnancies did not result in a live birth. A 2025 Dutch cohort by Boxem et al., published in BMC Medicine (2,528 first pregnancies), provided more precise relative risks: using age 30–34 as the reference, the miscarriage odds ratio (OR) was 2.03 (95% CI 1.51–2.72) at 35–39, and as high as 4.24 (95% CI 2.45–7.36) at 40 and older. This cohort also found that time to pregnancy (TTP) had not significantly worsened at 35–39, and declined clearly only at 40 and older (fecundability ratio around 0.59)—again confirming that “quality has problems before quantity.”
Trisomy 21 risk: the chromosomal condition most discussed in advanced-age pregnancy
Among live-born babies, the most common chromosomal trisomy is trisomy 21 (Down syndrome). Maternal-age-specific risk figures based on the classic Cuckle/Hook curves and systematically summarized by Morris et al. (2007, American Journal of Medical Genetics) are about 1/1250 at age 25, 1/350 at 35, 1/100 at 40, and 1/30 at 45. That means the risk of a woman aged 40 carrying a fetus with trisomy 21 is more than ten times the risk at age 25. This is why prenatal screening and diagnosis (NIPT, amniocentesis, etc.) are widely recommended in advanced-age pregnancy.
Live-birth rates with assisted reproduction: an “off-a-cliff” curve
The following are industry figures (not peer-reviewed, and definitions vary across reproductive centers; use only as a rough scale reference): live-birth rate per autologous-egg IVF cycle is around 45%–55% below 35, 20%–30% at 38–40, 10%–18% at 41–43, 2%–5% at 44–45, and 1%–3% at 46–47. This curve closely echoes the earlier curve for “aneuploidy rate”—it is essentially the projection of declining egg quality onto the live-birth outcome.
Two details also matter when reading this curve. First, “live-birth rate” usually means the probability of live birth per embryo transfer or per initiated cycle, and registries define this differently; directly comparing figures from two systems is not fair. Second, it measures a “population average,” while the result of one specific IVF attempt depends jointly on embryo quality, endometrial receptivity, laboratory performance, and luck. For an individual, there are only two outcomes, “success” or “not success”; there is no intermediate state such as “60% successful.” These figures are useful during the decision stage to understand the scale of probabilities and set expectations for the number of attempts, rather than predicting one specific outcome.
Two iron rules for reading the figures
First, these are all population probabilities; at the same age of 40, AMH, antral follicle count (AFC), and overall health can be worlds apart. Second, focus on “ovarian age,” rather than the age on your identity card: someone aged 38 can have reserve resembling that of a 45-year-old, while someone aged 43 may still have usable follicles. Only a complete assessment to locate “where you are on the curve” makes a conclusion meaningful.
Four. Risks and benefits: make the full calculation explicit

Actual view of a Philippine waterfall; unrelated to the medical evidence in this article.
To bring those figures into a real decision, consider both sides at once: what medicine can do for you, and which risks are inherent to age and cannot be avoided.
The benefit side: 40+ is not a “death sentence”
Today there are more feasible pathways than 20 years ago. People with adequate ovarian reserve can use their time window to try naturally or combine ovulation induction with intrauterine insemination (IUI); those with low reserve or tubal factors may use in vitro fertilization (IVF) to concentrate attempts over a shorter period; for recurrent miscarriage or high risk of age-related embryonic abnormalities, PGT-A can screen out most chromosomally abnormal embryos before transfer and reduce the burden of “conceive then lose”; when the woman's own egg quality is the main constraint, donated eggs can substantially bypass the “wall of egg age.” In practice, it is not unusual to see people in their early 40s successfully give birth through appropriately managed assisted reproduction.
The risk side: the cost of maternal age is real
Complication risks in advanced-age pregnancy rise in parallel, including gestational diabetes, preeclampsia, preterm birth, placental abnormalities, and cesarean delivery. These risks follow maternal age, rather than the “source of the egg”—even with donated eggs, the recipient's own physiological burden of pregnancy remains. In addition, the miscarriage and fetal chromosomal-abnormality risks mentioned above are background risks that every option can only “reduce,” not “eliminate.”
Three common misconceptions, unpacked one by one
- The frightening narrative that “after a certain age you absolutely cannot give birth.” This misreads a population curve and creates unnecessary age anxiety. The reality is a continuous decline with enormous individual variation.
- “Egg freezing = fertility insurance.” Egg freezing preserves the quality of the eggs at “the moment they are retrieved,” but at the time of a future pregnancy, maternal age still determines pregnancy complication risk; and thawing, fertilization, implantation, and live birth all have losses. It is an option, not insurance.
- “IVF can guarantee a pregnancy.” The value of PGT-A is reducing miscarriage due to aneuploidy; it does not increase the embryo's underlying potential or guarantee a live birth. Describing it as “mandatory at an advanced age, and if done, you will succeed” is exaggeration in the other direction.
These points lead to two often-asked pathways worth unpacking. First, who is PGT-A suitable for? It offers “clear benefit” for people with recurrent pregnancy loss, repeated implantation failure, and high risk of chromosomal abnormalities due to age—by screening out chromosomally abnormal embryos, it reduces the burden of “conceive then lose.” But it does not increase the total number of usable embryos and cannot help when “there are no euploid embryos to use.” It should therefore not be described as “mandatory at an advanced age.” Second, when the quality of one's own eggs is the main limitation, donor eggs can substantially bypass the “wall of egg age”: success depends more on the donor's age than on the recipient's, and live-birth chances are markedly higher than with autologous eggs at the same recipient age. But the recipient's pregnancy complications remain, and the process involves ethical, legal, and waiting-period issues. It is a “rational option,” rather than a synonym for “giving up.”
A decision framework that can be put into practice
Break “I want a baby” into three answerable questions: ① Where on the curve are my ovarian reserve and overall health? ② Can I accept the complication and miscarriage risks of pregnancy at an advanced age, and am I emotionally prepared for several attempts? ③ How much time remains in my window, and what can my budget and energy support? Taken together, the answers point toward one path: “try naturally / assisted reproduction / donor eggs / or set the idea aside for now.”
Five. Clinical advice: bring your test results to the consultation

Forest stream in Bukidnon; an actual location unrelated to the medical evidence in this article.
The most practical first step is not looking up numbers online, but taking a complete set of information to a reproductive medicine department. This checklist is written for women who are uncertain and for clinicians responsible for oversight.
- Do not be frightened by one AMH result or reach a conclusion from it. AMH is a snapshot at one point in time and may vary with menstrual cycle, test method, and assay. It indicates “how much reserve,” not “whether you can conceive,” and cannot independently establish the end point of fertility.
- Bring the basic reports: AMH, reproductive hormones on menstrual-cycle days 2–3 (FSH, E2, LH), antral follicle count (AFC) on transvaginal ultrasound, partner semen analysis, and a list of previous pregnancies, chronic conditions, and medications. Together, these can locate your true position on the age curve.
- Use the time window: The mainstream recommendation is referral to a reproductive specialist as soon as someone ≥40 begins trying to conceive. By contrast, those <35 may try for about one year first, and those 35–40 for six months; people 40+ do not follow the “wait a year first” timetable.
- Put all options on the table and compare them together: trying naturally / ovulation induction + IUI / IVF / PGT-A / donor eggs correspond to different ages, reserves, causes, budgets, and emotional capacity. None is a “standard answer.”
- Manage the foundations for pregnancy at the same time: weight, blood glucose, thyroid function, and blood pressure seem unrelated to fertility but determine “whether a pregnancy can remain stable.” Health management before conception is itself part of success probability.
- Calculate the costs before deciding: informed choice is a prerequisite—success rates, possible risks, expenses (some assisted-reproduction services are covered by insurance, but far from all; PGT and imported medicines are often out-of-pocket), and “how many attempts at most” should all be discussed clearly with the treating clinician in advance.
Another often-overlooked layer is psychological and relationship readiness. Fertility decisions after 40 often combine many variables—career, existing children, care for parents, partner preferences, and the emotional motivation behind “having one more.” Trying and treatment take a long time and fluctuate, and emotional stamina matters at least as much as medical factors. Before the appointment, consider discussing your “bottom line” with your partner (or support network): if repeated attempts do not work, would you move to donor eggs, adoption, or set the plan aside? Drawing that line early reduces internal conflict during the process and avoids pushing both body and mind into a corner through repeated disappointment. Medicine offers many options, but “how far to go before stopping” is a decision only you can make once informed.
A boundary reminder about “insurance coverage”
On 2026-08-19, China's National Healthcare Security Administration announced that all 31 provinces had included appropriate assisted-reproduction services in insurance; in the first half of 2026, related visits reached 1.7096 million, insurance spending exceeded 1.9 billion yuan, and around 139,700 newborns were supported, according to the official announcement. Insurance lowers the cost barrier, but does not change age-related success rates; pre-treatment examinations, imported stimulation drugs, PGT screening, and annual embryo-freezing fees often remain out-of-pocket. Do not mistake “reimbursable” for “it will work.”
Six. Quick-reference literature for clinicians
The original sources below are grouped by evidence type; each answers a different question, and they are not interchangeable:
- [1] Natural conception probability (cohort): Dunson DB, Baird DD, Colombo B. Changes with age in the level and duration of fertility in the menstrual cycle. Hum Reprod. 2002;17(5):1272–1276. Trying-to-conceive cohort n=782; describes age-related decline in per-cycle conception probability (around 0.06 at 40–44).
- [2] Age-related fertility decline (cohort): Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol. 2004;103(1):51–56. About 18% of women aged 35–39 had not conceived after one year.
- [3] Miscarriage rate (registry study): Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320:1708–1712. Danish registry n=634,272; spontaneous miscarriage 8.9% at ages 20–24 → 74.7% at 45+.
- [4] Relative risk of miscarriage (cohort): Boxem MC, et al. BMC Med. 2025. Dutch cohort n=2,528 first pregnancies; miscarriage OR 2.03 (95% CI 1.51–2.72) at 35–39, OR 4.24 (95% CI 2.45–7.36) at ≥40.
- [5] Aneuploidy rate (large dataset): Franasiak JM, et al. The nature of aneuploidy with increasing age: a repetitive DNA polymorphism study. Fertil Steril. 2014;101(3):656–663. n=15,169 trophectoderm biopsies; aneuploidy rate >62% at 40+, >90% at 45+.
- [6] Maternal age risk of trisomy 21 (review): Morris JK, et al. Am J Med Genet A. 2007 (summary of Cuckle/Hook curves). Age 25: 1/1250; 35: 1/350; 40: 1/100; 45: 1/30.
- [Industry statistics] Autologous-egg IVF live-birth rates per cycle (not peer-reviewed, varying center definitions): <35 around 45%–55%; 38–40 around 20%–30%; 41–43 around 10%–18%; 44–45 around 2%–5%; 46–47 around 1%–3%.
Seven. Conclusion: turn “do I want to?” into “what should I do?”

Landmark in Vigan's historic district; an actual location unrelated to the medical evidence in this article.
Back to the AMH 0.6 lab report at the beginning. It should help make things clearer, rather than more frightening. Fertility does decline with age, but the decline is continuous and individual, with much room for medical intervention along the way. What is truly regrettable is not “being 40,” but either making a hasty irreversible decision because of a frightening interpretation or spending time that could have been used to act in repeated anxiety.
It must also be acknowledged that fertility decisions after 40 are never only medical questions. Career stage, existing children, care for parents, partner preferences, and the emotions behind “having another child” all enter the picture represented by that lab result. Medicine can tell you “where the probabilities and boundaries are,” but cannot answer “is it worth it?” That is why this article repeatedly returns to “bring your test results and make a shared decision with a clinician”—not to hand the decision to the doctor, but to let you hold the steering wheel while fully informed. Outside voices, including this article, are only maps; the actual route can be drawn only by you and a treating clinician whose goals align with yours.
So when “should I have a child?” faces someone 40+, the most useful stance is not to issue a verdict based on one number, but to translate the decision into questions that can be answered: where is my reserve? What is my health foundation? How much time and capacity do I have? Then bring a complete set of test results to a reproductive-medicine clinician, calculate these probabilities, risks, and windows together, and decide on the next step.
For women 40+, the most important card in hand when it comes to fertility is never a “miracle plan,” but the right to be informed—knowing what the curve looks like tells you where you stand and which way to go.
If you remember only one sentence: if you want a child after 40, do not be deterred by one AMH number, and do not be lulled by optimism that “you can still have a baby”; bring your test results to a clinician and calculate probability, risk, and time window together. That answer will be more reliable than any online rumor. People who are informed always have more choice than people who are anxious.
Supplementary research and evidence boundaries:
Age-related fertility decline can be referenced in ACOG's Female Age-Related Fertility Decline Committee Opinion and ASRM documents on fertility evaluation and age-related fertility decline; egg aneuploidy and live-birth outcomes should be interpreted using cohort research and data registered by individual centers. Guidelines and cohorts describe population probabilities and cannot replace individual assessment; AMH/AFC are used mainly to predict response to ovarian stimulation and should not be used alone to determine natural-conception capacity or “absolute infertility.” Benefits of donor eggs, PGT-A, and other paths depend on indication, laboratory procedures, and local regulations; existing research does not support describing any pathway as “insurance.”
Disclaimer:
This is health education compiled from public literature and policies available through 2026-10, not individualized medical advice. Fertility, pregnancy risks, and assisted-reproduction success rates are highly individual. For specific decisions, bring complete test results to a reputable reproductive medicine/obstetrics and gynecology service and assess them together with the treating clinician. Industry statistics in this article are not peer-reviewed and use inconsistent definitions; they serve only as a rough scale reference. Coverage and reimbursement percentages follow the latest local insurance catalog.
References: [1] Dunson et al., 2002, Hum Reprod; [2] Dunson et al., 2004, Obstet Gynecol; [3] Nybo Andersen et al., 2000, BMJ; [4] Boxem et al., 2025, BMC Med; [5] Franasiak et al., 2014, Fertil Steril; [6] Morris et al., 2007, Am J Med Genet A. Mechanism data refer to follicle-depletion studies by Faddy et al. 1992 and Gougeon 2004. Official data: National Healthcare Security Administration announcement of 2026-08-19 on insurance coverage for assisted reproduction. Industry figures are labeled “not peer-reviewed.”
Read the source material
- ACOG: Having a baby after age 35
- ASRM: Testing and interpreting measures of ovarian reserve
- ACOG: Treating infertility
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


